Investigators conducted this subanalysis among patients aged 20 to 27 years, using data from the National Growth and Health Study to determine potential racial differences in left ventricular mass among female patients with obesity.
Cardiovascular (CV) risk factors and left ventricular mass index (LVMI) significantly differed between Black and White young adult female patients classified as being obese, according to data presented by investigators from The Heart Institute, Cincinnati Children’s Hospital Medical Center,1 at the American Society for Preventive Cardiology’s Congress on CVD Prevention, held in Arlington, Texas, July 21-23.
“Our aim was to utilize an existing longitudinal data set of Black and White females to evaluate racial differences in the impact of CV risk factors on adiposity measured by different modalities and to determine the contribution of adiposity to increased LVM,” the study investigators wrote.
There were 553 patients in their overall cohort, of whom 305 were Black and 248 White. Data were from the National Growth and Health Study and encompassed demographics, medical history, laboratory findings, anthropometrics (an individual’s physical measures of size, form, and functional capacity2), and imaging, which itself included dual energy x-ray absorptiometry (DEXA), MRI (abdominal subcutaneous and visceral fat), and echocardiogram (ECG). The bookends used were age at first DEXA scan (20-21 years) and age at final ECG (24-27 years).
Of the 18 CV risk variables examined at baseline, with a P value of ≤ .05 considered statistically significant, the following were increased in the Black patient vs the White patient cohort:
Only total cholesterol (180.2 [34.0] vs 170.0 [33.0] mg/dL), total triglycerides (109.7 [56.6] vs 86.3 [45.0] mg/dL), and high-density lipoprotein cholesterol (53.9 [14.5] vs 50.5 [12.5]) were higher among the White patients.
In particular, the investigators noted that the disparity in LVMI was considered statistically significant (P < .001) and that their findings overall demonstrate potential for significant racial differences in CV risk factors by young adulthood.
To start to close these CV risk factor disparity gaps, future studies need to examine how social determinants of health and various adiposities (eg, central vs peripheral, subcutaneous vs visceral), measured in different ways, contribute to the disparate outcomes, the authors concluded.
Potential limitations on these findings are that the study population comprised only female patients who were Black or White and that LVMI was measured only by ECG, “which is less accurate than cardiac MRI,” the authors wrote.
References
1. Sill J, Woo J, Urbina E. Racial differences in cardiovascular risk factors and the development of left ventricular hypertrophy. Presented at: ASPC Congress on CVD Prevention; July 21-23, 2023; Arlington, Texas. Poster 115.
2. Anthropometry. The National Institute for Occupational Safety and Health. Updated August 30, 2022. Accessed August 29, 2023. https://www.cdc.gov/niosh/topics/anthropometry/default.html#:~:text=Print-,Anthropometry,%2C%20form%2C%20and%20functional%20capacities
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More